Waters™

Application Note

Analysis of Drugs of Abuse Using XBridge Shield RP₁₈

Waters Corporation



For forensic toxicology use only.

This is an Application Brief and does not contain a detailed Experimental section.

Abstract

This application brief highlights the analysis of drugs of abuse using Bridge Shield RP₁₈ Columns.


Introduction

Benzodiazepines, such as clonazepam, bromazepam, lorazepam and flunitrazepam area class of drugs with sedative, hypnotic, anxiolytic, anti-convulsant, amnestic, and muscle relaxant properties. They are considered minor tranquilizers and have a high potential for abuse. MDA is the parent drug of MDMA, also known as Ecstasy. They are commonly abused, amphetamine – derived recreational drugs.

$$H_2N$$


1. MDMA


2. MDA



3. Bromazepam

4. Lorazepam





5. Clonazepam

6. Flunitrazepam

Experimental

Test Conditions

Columns: XBridge Shield RP $_{18}$ 4.6 X 100 mm, 3.5 μ m p/n:

186003044

Mobile phase A: H_2O

Mobile phase B: ACN

Mobile phase C: 100 mM NH₄HCO₃, pH 9.6

Flow rate: 0.6 mL/min

Injection volume: 10 μ L

Sample Concentration and Diluent: 10 μ g/mL in H_2O

Temp.: 40 °C

Sampling Rate: 5 points /second

Detection: UV @ 210 nm

Time Constant: 1.0

Needle Wash: 5/95 MeOH/H₂O

Instrument: Alliance 2695 with 2996 PDA


System Suitability Parameters

	Retention Time (min)	USP Tailing Factor	Width at 4.4%	USP Resolution
MDA	3.32	0.98	0.181	
MDMA	3.66	1.21	0.190	2.14
Bromazepam	5.16	1.05	0.223	8.28
Lorazepam	8.13	0.97	0.209	16.68
Clonazepam	8.60	0.97	0.209	2.81
Flunitrazepam	9.14	0.98	0.208	3.28

Gradient

Time(min)	%A	%B	%C
0	63	32	5
3	63	32	5
7	45	50	5
9	45	50	5
10	63	32	5
12	63	32	5

Results and Discussion



Featured Products

Alliance HPLC https://www.waters.com/514248

WA60202, June 2007

© 2021 Waters Corporation. All Rights Reserved.